|
TTC26 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-15 |
| Normal-vs-Stage2 |
4.23559999995771E-06 |
| Normal-vs-Stage3 |
5.05928632321684E-13 |
| Normal-vs-Stage4 |
1.79867232219522E-12 |
| Stage1-vs-Stage2 |
2.580600E-01 |
| Stage1-vs-Stage3 |
1.769760E-01 |
| Stage1-vs-Stage4 |
7.081200E-03 |
| Stage2-vs-Stage3 |
7.899500E-02 |
| Stage2-vs-Stage4 |
1.109580E-02 |
| Stage3-vs-Stage4 |
2.265800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.34889999999722E-05 |
| Normal-vs-Asian |
1.27480004330494E-09 |
| Caucasian-vs-AfricanAmerican |
2.322800E-01 |
| Caucasian-vs-Asian |
9.732600E-01 |
| AfricanAmerican-vs-Asian |
2.423400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62725388719309E-12 |
| Male-vs-Female |
2.615700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64668279012403E-12 |
| Normal-vs-Age(41-60Yrs) |
2.83983947468869E-12 |
| Normal-vs-Age(61-80Yrs) |
5.7308602308126E-12 |
| Normal-vs-Age(81-100Yrs) |
8.39910000000055E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.927000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.551000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.389600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.744000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.210800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.393800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.900030E-02 |
| Classical-VS-Follicular |
9.181000E-01 |
| Classical-VS-Other |
2.803400E-01 |
| Classical-VS-Normal |
2.81220047249064E-10 |
| Tall-VS-Follicular |
5.653600E-02 |
| Tall-VS-Other |
8.492800E-01 |
| Tall-VS-Normal |
8.49076364772827E-12 |
| Follicular-VS-Other |
3.692800E-01 |
| Follicular-VS-Normal |
7.37189997934706E-09 |
| Other-VS-Normal |
5.161800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.0991207943789E-14 |
| Normal-vs-N1 |
5.63440405443316E-11 |
| N0-vs-N1 |
1.255020E-01 |
|
|
